These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16824902)

  • 1. Pathophysiology, diagnosis, and management of dyslipidemia.
    Gau GT; Wright RS
    Curr Probl Cardiol; 2006 Jul; 31(7):445-86. PubMed ID: 16824902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipids for psychiatrists - an overview.
    Young IS
    J Psychopharmacol; 2005 Nov; 19(6 Suppl):66-75. PubMed ID: 16280339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of lipid-lowering drug therapy in children and adolescents.
    Avis HJ; Vissers MN; Wijburg FA; Kastelein JJ; Hutten BA
    Curr Opin Investig Drugs; 2009 Mar; 10(3):224-31. PubMed ID: 19333879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors.
    Davidson MH
    Am J Manag Care; 2007 Dec; 13 Suppl 10():S260-9. PubMed ID: 18095776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing dyslipidemia in chronic kidney disease.
    Harper CR; Jacobson TA
    J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives on dyslipidemia and coronary heart disease in women: an update.
    Bittner V
    Curr Opin Cardiol; 2006 Nov; 21(6):602-7. PubMed ID: 17053411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment of dyslipidemia--what's left in the pipeline?
    Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
    ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid management in children.
    Zappalla FR; Gidding SS
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):171-83. PubMed ID: 19217518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening adolescents for lipid disorders: what is the best approach?
    Jenssen BP; Jacobson MS
    Adolesc Med State Art Rev; 2008 Dec; 19(3):507-20, x. PubMed ID: 19227389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of dyslipidemia in the emergency department: impact of cholesterol testing on subsequent therapy.
    Blomkalns AL; O'Connell EM; Eady CE; Lindsell CJ; Gibler WB
    Am Heart J; 2006 Dec; 152(6):1182-6. PubMed ID: 17161073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis.
    Petrella RJ; Merikle E; Jones J
    Clin Ther; 2007 Apr; 29(4):742-50. PubMed ID: 17617298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary management of dyslipidemia in high-risk patients: targets still not met.
    Yan AT; Yan RT; Tan M; Hackam DG; Leblanc KL; Kertland H; Tsang JL; Jaffer S; Kates ML; Leiter LA; Fitchett DH; Langer A; Goodman SG;
    Am J Med; 2006 Aug; 119(8):676-83. PubMed ID: 16887414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation critique of state of the art dyslipidemia management in general and with a special emphasis on the Indian population.
    Whayne TF
    Indian Heart J; 2007; 59(3):218-25. PubMed ID: 19124929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma lipoprotein abnormalities in hemodialysis patients--clinical implications and therapeutic guidelines.
    Shoji T; Nishizawa Y
    Ther Apher Dial; 2006 Aug; 10(4):305-15. PubMed ID: 16911182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
    Chapman MJ; Sposito AC
    Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid management in the geriatric patient.
    Nair AP; Darrow B
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.